Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Japan's MHLW approved Novocure's Optune Pax for adult patients with unresectable locally advanced pancreatic cancer, used concomitantly with gemcitabine and nab-paclitaxel. The approval is based on the Phase 3 PANOVA-3 trial, which met its primary endpoint with a statistically significant improvement in median overall survival versus chemotherapy alone. Optune Pax was previously approved by the FDA in February 2026 and received a CE Mark in June 2026; the Japan approval adds a third major market for the pancreatic cancer indication.
Key figures
- Drug Name
- Optune Pax
- Phase Of Trial
- Phase 3
- Grade 1 2 skin aes
- 76.3% of Optune Pax-treated participants
- Grade 3plus skin aes
- 7.7% (21 patients)
- Japan five year relative survival
- 12%
- Japan pancreatic cancer diagnoses annual
- 46000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.